Porras Bueno Cristian Orlando: Wrote and reviewed the manuscript and was involved in data acquisition and analysis.

Saldarriaga Giraldo Clara Ines: Conceived and designed the study and reviewed the manuscript.

Roncancio Villamil Gustavo Eduardo: Conceived and designed the study and reviewed the manuscript.

Álvarez Barreneche María Fernanda: Conceived and designed the study and reviewed the manuscript.

1. Miloslavsky E, Unizony S. The Heart in Vasculitis. Rheum Dis Clin North Am [Internet]. 2014;40(1):11–26. Available from: http://dx.doi.org/10.1016/j.rdc.2013.10.006

2. Kitching AR, Anders HJ, Basu N, Brouwer E, Gordon J, Jayne DR, et al. ANCA-associated vasculitis. Nat Rev Dis Prim [Internet]. 2020;6(1):71. Available from: http://dx.doi.org/10.1038/s41572-020-0204-y

3. Bond M, Fagni F, Moretti M, Bello F, Egan A, Vaglio A, et al. At the Heart of Eosinophilic Granulomatosis with Polyangiitis: into Cardiac and Vascular Involvement. Curr Rheumatol Rep [Internet]. 2022;24(11):337–51. Available from: https://doi.org/10.1007/s11926-022-01087-1

4. Massussi M, Scotti A, Lip GYH, Proietti R. Left ventricular thrombosis : new perspectives on an old problem. Eur Heart J. 2021;7:158–67.

5. Franks TJ, Koss MN. Pulmonary capillaritis. Curr Opin Pulm Med. 2000;6:430–5.

6. Shuai ZW, Lv YF, Zhang MM, Hu ZY. Clinical analysis of patients with myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis. Genet Mol Res. 2015;14(2):5296–303.

7. Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Care Res (Hoboken). 1999;42(3):421–30.

8. Silveira LH. Cardiovascular Manifestations of Systemic Vasculitides. Curr Rheumatol Rep. 2020;22:72.

9. Savvoulidis P, Butler J, Kalogeropoulos A. Cardiomyopathy and Heart Failure in Patients with Human Immunodeficiency Virus Infection. Can J Cardiol [Internet]. 2018;35(3):299–309. Available from: https://doi.org/10.1016/j.cjca.2018.10.009

10. Brinkman K, Hofstede HJM, Burger DM, Smeitink JAM, Koopmans PP. Adverse effects of reverse transcriptase inhibitors : mitochondrial toxicity as common pathway. AIDS. 1998;12:1735–44.

11. Lewis W, Copeland WC, Day BJ. Mitochondrial DNA depletion, oxidative stress, and mutation: Mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab Investig. 2001;81(6):777–90.

12. Lewis W, Grupp IL, Günter G, Hoit B, Morris R, Samarel AM, et al. Cardiac Dysfunction Occurs in the HIV-1 Transgenic Mouse Treated with Zidovudine. Lab Investig. 2000;80(2):187–97.

13. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995;333(17):1099–105.

14. Comereski CR, Kelly WA, Davidson TJ, Warner WA, Hopper LD, Oleson FB. Acute Cardiotoxicity of Nucleoside Analogs FddA and FddI in Rats. Fundam Appl Toxicol Off J Soc Toxicol. 1993;20:360–4.

15. Alvi RM, Neilan AM, Tariq N, Awadalla M, Afshar M, Banerji D, et al. Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure. JACC. 2018;72(5):518–30.

16. Liu C, Ferrari VA, Han Y. Cardiovascular Magnetic Resonance Imaging and Heart Failure. Curr Cardiol Rep. 2021;23(4):35.

17. Karamitsos TD, Arvanitaki A, Karvounis H, Neubauer S, Ferreira V. Myocardial Tissue Characterization and Fibrosis by Imaging. JACC Cardiovasc Imaging. 2019;13(5):1221–34.

18. Navas-nacher EL, Colangelo L, Beam C. Risk Factors for Coronary Heart Disease in Men 18 to 39 Years of Age. Ann Intern Med. 2001;134:433–9.

19. Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology / Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis Care Res (Hoboken). 2021;73(8):1088–105.

20. Task A, Members F, Mcdonagh TA, United C, Gardner RS, Force T, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribut. Eur Heart J. 2021;42:3599–726.

21. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byunt JJ, Colvin MM, et al. 2022 AHA / ACC / HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895–1032.